Characterization of Plasma Immunoglobulin G Responses in Elite Neutralizers of Human Cytomegalovirus
- 16 August 2022
- journal article
- research article
- Published by Oxford University Press (OUP) in The Journal of Infectious Diseases
- Vol. 226 (9) , 1667-1677
Abstract
Background: Human cytomegalovirus (HCMV) is the most common infectious complication of organ transplantation and cause of birth defects worldwide. There are limited therapeutic options and no licensed vaccine to prevent HCMV infection or disease. To inform development of HCMV antibody-based interventions, a previous study identified individuals with potent and broad plasma HCMV-neutralizing activity, termed elite neutralizers (ENs), from a cohort of HCMV-seropositive (SP) blood donors. However, the specificities and functions of plasma antibodies associated with EN status remained undefined.Methods: We sought to determine the plasma antibody specificities, breadth, and Fc-mediated antibody effector functions associated with the most potent HCMV-neutralizing responses in plasma from ENs (n = 25) relative to that from SP donors (n = 19). We measured antibody binding against various HCMV strains and glycoprotein targets and evaluated Fc-mediated effector functions, antibody-dependent cellular cytotoxicity (ADCC), and antibody-dependent cellular phagocytosis (ADCP).Results: We demonstrate that ENs have elevated immunoglobulin G binding responses against multiple viral glycoproteins, relative to SP donors. Our study also revealed potent HCMV-specific antibody-dependent cellular cytotoxicity and antibody-dependent cellular phagocytosis activity of plasma from ENs.Conclusions: We conclude that antibody responses against multiple glycoprotein specificities may be needed to achieve potent plasma neutralization and that potently HCMV elite-neutralizing plasma antibodies can also mediate polyfunctional responses.Keywords
All Related Versions
Funding Information
- National Center for Advancing Translational Sciences
- National Institutes of Health (UL1TR002553, 3P01AI129859, 2T32AI052077-16A1)
- Biostatistics, Epidemiology and Research Design Methods
- Translating Duke Health Initiative
- Duke Center for Human Systems Immunology
- Else Kröner-Fresenius Foundation (2016-A126)
- Medearis CMV Scholar Award
- Duke University School of Medicine
- National Institute of Allergy and Infectious Diseases
This publication has 46 references indexed in Scilit:
- Fetal Human Cytomegalovirus Transmission Correlates with Delayed Maternal Antibodies to gH/gL/pUL128-130-131 Complex during Primary InfectionPLOS ONE, 2013
- Antibodies against the gH/gL/UL128/UL130/UL131 Complex Comprise the Majority of the Anti-Cytomegalovirus (Anti-CMV) Neutralizing Antibody Response in CMV Hyperimmune GlobulinJournal of Virology, 2012
- Immune-Correlates Analysis of an HIV-1 Vaccine Efficacy TrialNew England Journal of Medicine, 2012
- B Cell Repertoire Analysis Identifies New Antigenic Domains on Glycoprotein B of Human Cytomegalovirus which Are Target of Neutralizing AntibodiesPLOS Pathogens, 2011
- Cytomegalovirus glycoprotein-B vaccine with MF59 adjuvant in transplant recipients: a phase 2 randomised placebo-controlled trialThe Lancet, 2011
- Isolation of Human Monoclonal Antibodies That Potently Neutralize Human Cytomegalovirus Infection by Targeting Different Epitopes on the gH/gL/UL128-131A ComplexJournal of Virology, 2010
- Vaccine Prevention of Maternal Cytomegalovirus InfectionNew England Journal of Medicine, 2009
- Mixed Cytomegalovirus Glycoprotein B Genotypes in Immunocompromised PatientsClinical Infectious Diseases, 2004
- Investigation of CMV disease in immunocompromised patientsJournal of Clinical Pathology, 2001
- The Uses of Tobit AnalysisReview of Economics and Statistics, 1980